RESEARCH ARTICLE | VOLUME 3, ISSUE 2 | OPEN ACCESS DOI: 10.23937/2474-1353/1510055

Clinical and Histopathological Comparison of Two Historical Series of 142 Wertheim-Meigs Operations Performed in a Reference Center in Brazil

Roney Cesar Signorini Filho1 , Leandro Freitas Colturato2, Guilherme Bicudo Barbosa3, Thaiane Silvério Fatibello Rosa3 and Luiz Henrique Gebrim4

1Surgical Oncology Department, Centro de Referência da Saúde da Mulher do Estado de São Paulo - Hospital Pérola Byington (CRSM), São Paulo, Brazil

2Residency Preceptor of Gynecology and Obstetrics Residency Training, Faculdade de Medicina de São José do Rio Preto - Hospital de Base (FAMERP), São José do Rio Preto, Brazil

3Residency Preceptor of Gynecology and Obstetrics Residency Training, Centro de Referência da Saúde da Mulher do Estado de São Paulo - Hospital Pérola Byington (CRSM), São Paulo, Brazil

4Centro de Referência da Saúde da Mulher do Estado de São Paulo - Hospital Pérola Byington (CRSM) and Full Professor, Universidade Federal de São Paulo (Unifesp-EPM), São Paulo, Brazil

*Corresponding author: Roney Cesar Signorini Filho, Chief, Surgical Oncology Department, Centro de Referência da Saúde da Mulher do Estado de São Paulo - Hospital Pérola Byington Avenida Brigadeiro Luis Antônio, 683 Bela Vista, São Paulo (SP), Brazil, Tel: +55-11-99993-7887, Fax: +55-11-3248-8113, E-mail: dr.roneycesar@hotmail.com

Received: April 15, 2017 | Accepted: June 10, 2017 | Published: June 12, 2017

Citation: Filho RCS, Colturato LF, Barbosa GB, Rosa TSF, Gebrim LH (2017) Clinical and Histopathological Comparison of Two Historical Series of 142 Wertheim-Meigs Operations Performed in a Reference Center in Brazil. Int J Womens Health Wellness 3:055. doi.org/10.23937/2474-1353/1510055

Copyright: © 2017 Filho RCS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract


Introduction

Cervical cancer is the third-leading cause of death from cancer in Brazilian female population. Treatment depends on the clinical stage of the disease according to the classification of the International Federation of Gynecology and Obstetrics (FIGO). Radical hysterectomy with pelvic lymphadenectomy, the "Wertheim-Meigs" surgery, is a key intervention for tumors restricted to the cervix.

Methods

This retrospective study aimed to compare clinical and pathologic data on two historical series (2001-2007 and 2011-2014) of 142 patients submitted to Wertheim-Meigs surgery. The medical records were reviewed with special emphasis on clinical findings and pathological features.

Results

The clinical profile of these patients, such as age (average age of 48), parity (average of 4 children), and smoking (21% of patients were smokers) remained similar. Regarding pathological data, there was an increasing prevalence of adenocarcinoma compared to squamous cell carcinoma. In the two series presented and excluding other rare histologies, the percentage of CEC fell from 87.3% to 71.4% (p = 0.045). Pelvic lymph node metastasis raised from 7.2% to 20.3% on the latest series (p = 0.040). Histological grade and stromal invasion remained stable in both series. Other variables as average tumor size (> 2 cm or > 4 cm) and lymphovascular invasion showed small differences between the two groups evaluated, without statistical significance.

Conclusion

Was observed an increase of adenocarcinomas and positive pelvic lymph nodes in the comparison of the two historical series. Although lymphovascular invasion, tumor size and deep stromal invasion are also important prognostic indicators, it did not show significant growth. We present an introduction to this subject of how two historical series of the same service are substantially different in terms of variables, approached in such a short time difference of only four years between them.

Keywords


Uterine cervical neoplasms, Gynecologic surgical procedures, Adenocarcinoma, Carcinoma squamous cell

Introduction


Cervical cancer is the third-leading cause of death from cancer in Brazilian female population. For the year 2016, in Brazil, 16,340 new cases of cervical cancer are expected, with an estimated risk of 15.85 cases per 100,000 women. In the period from 2005 to 2009, overall survival was around 61% [1,2]. Human Papilloma Virus (HPV) is the most important etiologic factor in majority of cases of cervical cancer, with HPV DNA identified in approximately 95% of malignant cervical lesions. Other risk factors such as low socio-economic status, tobacco smoking, sexual habits, HIV, other sexually transmitted diseases, long-term oral contraceptive use, certain micronutrient deficiencies and genetic susceptibility have been suggested as determinants [3]. Treatment depends on the clinical stage of the disease according to the classification of the International Federation of Gynecology and Obstetrics (FIGO) [4,5].

Brazil still needs appropriate studies to assess the behavior and profile of this disease in our population. The surgical oncology service at Hospital Pérola Byington women's health reference center is reference for treatment of pelvic gynecologic malignancies in the State of São Paulo. In 2015, the women's health reference center performed 556 oncological procedures of the genital tract ranging from low-complexity surgery to high-complexity surgery. Of these surgeries performed, nearly 30% are related to cervical cancer or intraepithelial lesions. Almost 3/5 of the diagnosed cases are locally advanced and treated with chemoradiotherapy. Considering 112 cases of invasive cervical cancer that underwent surgery of any kind, including cone biopsy or physical examination under narcosis, only 26% were eligible for radical hysterectomy (Querleu-Morrow type C) [6].

Radical hysterectomy with pelvic lymph adenectomy, the "Wertheim-Meigs" surgery, is a key intervention for tumors restricted to the cervix or contiguous to upper vagina. The procedure is mainly indicated in the following conditions: microscopic tumor larger than 7 mm in length or 3 mm in stromal depth and macroscopic tumors less than 4 cm in diameter (stage IA2, IB1 and IIA1). According to the NCCN, this surgery could also be indicated in stages IB2, although the most usual approach is to use radiotherapy with concurrent chemotherapy in such cases [4,7]. Alternatively, ESMO suggest neoadjuvant chemotherapy followed by radical hysterectomy in selected cases, although it is not a standard practice [8].

In the final data of an anatomopathological examination, such as histologic type, tumor size, lymphovascular invasion, histological grade, stromal invasion, and lymph node status, all of them are prognostic and critical factors to define the adjuvant therapy [4,9]. A randomized trial of surgery versus radiotherapy for patients with stage IB1 to stage IIA cervical cancer demonstrated no difference in survival. The patients in this trial did not receive chemotherapy, and 84% of patients in the surgical arm with tumors measuring > 4 cm required postoperative radiotherapy. Morbidity was noted to be greater in patients who received both modalities, and therefore current recommendations are to try to use a single modality [10].

Methods


This study aimed to compare clinical and pathologic data on two historical series (2001-2007 and 2011-2014) of patients submitted to radical hysterectomy with pelvic lymph adenectomy (Wertheim-Meigs surgery). There was performed a retrospective review of 142 patients with clinical FIGO stage IA2-IIA1 cervical cancer, who were treated by surgery in our service between 2001-2007 (83 cases) and between 2011-2014 (59 cases). Data were retrieved from the hospital registry.

The medical records of these patients were reviewed with special emphasis on clinical findings such as patient age, smoking and parity, and pathological features. The tumors were classified according to cell type as follows: squamous cell carcinoma, adenocarcinoma and other unusual types, pathologic grade of well, moderately or poorly differentiated, greatest diameter of the primary tumor (larger than 2 or 4 cm); lymphovascular invasion; deep stromal invasion (more than 1/3 of cervical thickness) and pelvic lymph node metastasis. Descriptive analysis was used for categorical variables, such as frequencies and percentages, in the two different series. Statistical analysis was performed using the chi-square test when applicable, at a significance level of 5% (p-value ≤ 0.05).

Results


We have observed, in this study, that the clinical profile of patients operated from 2001 to 2007, and from 2011 to 2014 remained similar for the following risk factors: age (average age of 48), parity (average of 4 children), and smoking (21% of patients were smokers) (Table 1). Regarding pathological data, we see an increasing prevalence of adenocarcinoma (endocervical adenocarcinoma, mucinous adenocarcinoma, and adenosquamous) compared to squamous cell carcinoma (SCC). In the two series presented and excluding other rare histologies, the percentage of CEC fell from 87.3% to 71.4% (p = 0.045). In turn, pelvic lymph node metastasis raised from 7.2% to 20.3% on the latest series (p = 0.040). Histological grade and stromal invasion remained stable in both series. Other variables as average tumor size (> 2 cm or > 4 cm) and lymphovascular invasion showed small differences between the two groups evaluated, without statistical significance (Table 2 and Figure 1).

Table 1: Clinical information. View Table 1

Table 2: Histopathological variables. View Table 2

Figure 1: Squamous cell carcinoma. Lymph node metastasis, Lymphovascular Invasion (LVI), tumor size > 2 cm and stromal invasion > 1/3.SCC (p = 0.045); lymph nodes + (p = 0.04); lymphovascular invasion, tumor diameter > 2 cm, estromal invasion: p > 0.05. View Figure 1

Discussion


HPV 16/18 account for two-thirds of cervical carcinomas in all continents. Persistent infection will result in the development of the premalignant Cervical Intraepithelial Neoplasia (CIN) or adenocarcinoma in situ. Various factors increase the development of persistent transformation, including cigarette smoking, long-term oral contraceptive use, high parity and co-infection with type 2 herpes simplex virus and the human immunodeficiency virus. Without treatment, the transition from dysplasia to invasive carcinoma may take years to decades to develop in most women. In addition, adenocarcinoma in situ appears to be more difficult to detect on Papanicolaou testing and this is thought to be one of the reasons for the increasing incidence of subtype of cervical cancer (HPV 18) [8,11]. The screening is realized through cytology each 3 years and with HPV and cytology co-testing every 5 years, preferred [7]. This combination demonstrated a slight increase in sensitivity for detection of CIN 2/3 (pre malign lesions). One limitation of the use of HPV testing in brazilian public medical service is the increased cost [2,12].

Studies have shown that over the past three decades, SCC of the cervix has been progressively decreasing in proportion to the increase of adenocarcinoma, also found in our study [13-17]. However, in a more current reality, this can be explained due to the better public access to the examination of cervical cytological screening. This examination has better effectiveness in identifying intraepithelial neoplasias and precursors of SCC in relation to precursors of adenocarcinomas. Positive pelvic lymph node is one of the most important prognostic factors in cervical cancer [4,7-9,13,18,19]. Increased rates of lymph node metastasis in the comparison of the two historical series maintained a close relationship with the concomitant growth of adenocarcinoma type. On the other hand, although was observed an increase of adenocarcinomas and positive pelvic lymph nodes in the comparison of the two historical series. Although lymphovascular invasion, tumor size and deep stromal invasion are also important prognostic indicators, it did not show significant growth.

In this context, a possible explanation to recommend a radical hysterectomy for cancers with poor prognostic factors and/or advanced locally is the limitation of tests recommended by the International Federation of Gynecology and Obstetrics (FIGO), which essentially recommends the completion of a thorough physical examination, associated with a minimum of subsidiary propedeutics, such as evaluation of the urinary tract, concerning the clinical staging of the disease. But, even imaging tests such as MRI and incisional biopsies may not give a proper assessment of stromal invasion, lymph node enlargement, invasion of isthmus and body of the uterus, which would contraindicate the surgical procedure when associated. Another reason may be the development and growth of surgical teams in the period surveyed towards a more aggressive approach against tumors of poorer prognosis. However, we have to assess whether this radicalism has reflected in better oncologic results with acceptable toxicity to the patient. This study is already underway.

Conclusion


Clearly, much remains to be known about the biological behavior, as well as the clinical and epidemiological profile of cervical cancer in Brazil. The study is only an introduction to this subject and of how two historical series of the same service are substantially different in terms of variables approached in such a short time (difference of only four years between series). Thus, we should not treat cervical cancer as a static condition, quite the contrary, it is full of variations, which depend on the population and the period studied.

References


  1. (2016) Estimativa. Incidência de câncer no Brasil.

  2. (2016) INCA. Diretrizes Brasileiras para o Rastreamento do Câncer do Colo Uterino, 2ª Edição revista, ampliada e atualizada. Ministério da Saúde.

  3. Dahiya N, Bachani D, Acharya AS, Sharma DN, Gupta S, et al. (2017) Socio-Demographic, Reproductive and Clinical Profile of Women Diagnosed with Advanced Cervical Cancer in a Tertiary Care Institute of Delhi. J Obstet Gynaecol India 67: 53-60.

  4. (2016) NCCN Comprehensive Cancer - Clinical Practice Guidelines in Oncology, Version 1.

  5. Burghardt E, Baltzer J, Tulusan AH, Haas J (1992) Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer 70: 648-655.

  6. Querleu D, Morrow CP (2009) Classification of Radical Hysterectomy. Gynecol Oncol 115: 314-315.

  7. Carter JS, Sonoda Y (2016) Cervical Cancer Guidelines.

  8. Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, et al. (2012) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol 23: 27-32.

  9. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, et al. (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 73: 177-183.

  10. Landoni F, Maneo A, Colombo A, Placa F, Milani R, et al. (1997) Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 350: 535-540.

  11. Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, et al. (2017) Cervical cancer: a global health crisis. Cancer.

  12. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 377: 1754.

  13. Colturato LF, Signorini RC, Gebrim LH, Fernandes RC, Oliani AH (2016) Lymph node micrometastases in initial stage cervical câncer and tumoral recurrence. Int J Gynaecol Obstet 133: 69-75.

  14. Barnholtz-Sloan J, Patel N, Rollison D, Kortepeter K, MacKinnon J, et al. (2009) Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity. Cancer Causes Control 20: 1129-1138.

  15. Wang SS, Carreon JD, Gomez SL, Devesa SS (2010) Cervical cancer incidence among 6 asian ethnic groups in the United States, 1996 through 2004. Cancer 116: 949-956.

  16. Howe HL, Wu X, Ries LA, Cokkinides V, Ahmed F, et al. (2006) Annual report to the nation on the status of cancer, 1975- 2003, featuring cancer among US - Hispanic/Latino populations. Cancer 107: 1711-1742.

  17. Leminen A, Paavonen J, Forss M (1990) Adenocarcinoma of the uterine cervix. Cancer 65: 53-59.

  18. Alvarez RD, Potter ME, Soong SJ, Gay FL, Hatch KD, et al. (1991) Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. Gynecol Oncol 43: 108-112.

  19. Tiltman AJ (2005) The pathology of cervical tumors. Best Pract Res Clin Obstet Gynaecol 19: 485-500.